Evaluation of the BT-1 serum assay for breast cancer

Article type: Research Article

Authors: Whitehurst, Maureen M.^{; *} | Aldenderfer, Paul H. | Sooy, Marlisa M. | Strelkauskas, Anthony J.

Affiliations: Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, USA

Correspondence: [*] Corresponding author: Maureen M. Whitehurst, Ph.D., BreasTek, Inc., 1313 Ashley River Road, Charleston, SC 29407, USA. Fax: +1 843 769 7603.

Abstract: The BT-1 assay which identifies a novel breast tumor associated serum analyte was performed for 143 patients previously diagnosed with breast cancer. Mucin tumor markers CA15-3/CA27-29 values were available for 50 patients and there was very minor overlap between patients positive by both tests. Patients' follow-up clinical status at sample draw was compared to BT-1 assay results. 27% patients originally diagnosed as Stage III who were evaluated ‘no disease’ had positive BT-1 values. 8% results in samples drawn within 90 days of chemotherapy initiation, whereas 23% 90 days of chemotherapy initiation. 50% breast cancer surgery had positive BT-1 values, suggesting that the BT-1 assay may be useful in identification women with more advanced disease at diagnosis.

DOI: 10.3233/HAB-1999-9304

Journal: Human Antibodies, vol. 9, no. 3, pp. 155-160, 1999